Want to see TSE:LOVE full AI Analyst Report?
LOVE Stock Chart & Stats
C$1.90
-C$0.04(-2.11%)
At close: 4:00 PM EDT
C$1.90
-C$0.04(-2.11%)
Day’s Range― - ―
52-Week RangeC$1.55 - C$2.07
Previous CloseN/A
Volume10.70K
Average Volume (3M)45.69K
Market Cap
C$196.58M
Enterprise ValueC$183.06
Total Cash (Recent Filing)C$21.81M
Total Debt (Recent Filing)C$37.00M
Price to Earnings (P/E)17.5
Beta0.33
Next Earnings
Nov 24, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding98,782,150
10 Day Avg. Volume37,006
30 Day Avg. Volume45,690
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.63
Price to Sales (P/S)1.55
P/FCF Ratio12.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$3.33Price Target Upside75.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.12
Revenue Forecast (FY)C$122.76M
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability GrowthSustained revenue expansion alongside a shift from losses to profitability indicates stronger market adoption and operating scale. This provides a durable base for funding growth, although recent margin trends require continued cost and product-mix discipline.
Market Share And DistributionBroad distribution and share gains across major provinces demonstrate effective brand execution and product velocity in the regulated market. Greater retail presence can reinforce customer awareness, listing retention and purchasing leverage over the medium term.
Capacity Expansion And Strategic PartnershipsExpanded cultivation and processing capacity should support additional volume while the Curaleaf agreement adds a potential channel for recurring wholesale demand. The existing footprint also offers further growth runway without requiring an entirely new production platform.
Bears Say
Margin CompressionRecent margin deterioration and weaker operating profit show that revenue growth is not translating consistently into earnings. Product mix, cultivation costs and operating expenses could constrain profitability until expanded infrastructure generates better yields and efficiency.
Volatile Free Cash FlowHeavy expansion investment and working-capital movements are reducing cash available after operations. Persistently uneven free cash flow could limit internally funded growth, increase reliance on credit and make returns from the capacity program more dependent on execution.
Competitive And Category PressureCannabis competition can weaken pricing, shelf access and product volumes, particularly in fast-changing categories such as live resin vapes. Sustaining share may therefore require targeted promotions and marketing investment, creating a persistent risk to margins and brand economics.
Cannara Biotech News
LOVE FAQ
What was Cannara Biotech’s price range in the past 12 months?
Cannara Biotech lowest stock price was C$1.55 and its highest was C$2.07 in the past 12 months.
What is Cannara Biotech’s market cap?
Cannara Biotech’s market cap is C$196.58M.
When is Cannara Biotech’s upcoming earnings report date?
Cannara Biotech’s upcoming earnings report date is Nov 24, 2026 which is in 92 days.
How were Cannara Biotech’s earnings last quarter?
Cannara Biotech released its earnings results on Jul 15, 2026. The company reported C$0.05 earnings per share for the quarter, the consensus estimate of C$0.05 by C$0.
Is Cannara Biotech overvalued?
According to Wall Street analysts Cannara Biotech’s price is currently Undervalued.
Does Cannara Biotech pay dividends?
Cannara Biotech does not currently pay dividends.
What is Cannara Biotech’s EPS estimate?
Cannara Biotech’s EPS estimate is 0.04.
How many shares outstanding does Cannara Biotech have?
Cannara Biotech has 98,782,150 shares outstanding.
What happened to Cannara Biotech’s price movement after its last earnings report?
Cannara Biotech reported an EPS of C$0.05 in its last earnings report, expectations of C$0.05. Following the earnings report the stock price went down -1.053%.
Which hedge fund is a major shareholder of Cannara Biotech?
Currently, no hedge funds are holding shares in TSE:LOVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cannara Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$3.33 (75.44% Upside)
C$3.33 (75.44% Upside)
Insider Transactions
Bought Shares
Worth C$125.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
159.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.13%
Trailing 12-Months
Company Description
Cannara Biotech
Cannara Biotech Inc., alongside its affiliated entities, specializes in the indoor cultivation, processing, and distribution of cannabis and related products across Canada. The company operates with a dual business model, encompassing both cannabis operations and real estate activities. Its diverse product portfolio is marketed under distinct brand names such as TRIBAL, nugz, and ORCHID CBD. Distribution is managed through both wholesale channels and online retail platforms. Established in 2017, Cannara Biotech Inc. maintains its headquarters in Saint-Laurent, Canada.
LOVE Company Deck
LOVE Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and financial picture: double-digit revenue growth (16% QoQ), continued profitability (adjusted EBITDA up 11% and 21 consecutive positive quarters), strengthened market penetration (national share gains and record monthly shares in Ontario and Alberta), accelerated capacity expansion and strategic partnerships (Medican acquisition, Blue River technology, CAD 21M Curaleaf agreement). Notable near-term negatives include lower quarterly free cash flow and operating cash flow versus the prior year driven by higher expansion capex, a modest dip in gross margin from product mix, higher receivables and inventory, and competitive pressures in certain categories. On balance, the highlights — consistent profitability, expanding distribution and market share, accelerated capacity rollout, and strategic deals — outweigh the lowlights tied to timing, investment-driven cash flow effects, and category competition.View all TSE:LOVE earnings summariesLOVE Stock 12 Month Forecast
Average Price Target
C$3.33
▲(75.44% Upside)
Technical Analysis
Jushi Holdings
―
Organigram Global
―
Auxly Cannabis Group
―
―
Grown Rogue International
―